key: cord-1043481-6jehu319 authors: Rezapour, Aziz; Souresrafil, Aghdas; Peighambari, Mohammad Mehdi; Heidarali, Mona; Tashakori-Miyanroudi, Mahsa title: Economic evaluation studies of programs against COVID-19: a systematic review of the literature date: 2020-11-21 journal: Int J Surg DOI: 10.1016/j.ijsu.2020.11.015 sha: 57501c6e8383e19a0499f7e8be2e8ea11de8b4ad doc_id: 1043481 cord_uid: 6jehu319 BACKGROUND: The COVID-19 pandemic has become a public health emergency and raised global concerns in about 213 countries without vaccines and with limited medical capacity to treat the disease. The COVID-19 has prompted an urgent search for effective interventions, and there is little information about the money value of treatments. The present study aimed to summarize economic evaluation evidence of preventing strategies, programs, and treatments of COVID-19. MATERIAL AND METHODS: We searched Medline/PubMed, Cochrane Library, Web of Science Core Collection, Embase, Scopus, Google Scholar, and specialized databases of economic evaluation from December 2019 to July 2020 to identify relevant literature to economic evaluation of programs against COVID-19. Two researchers screened titles and abstracts, extracted data from full-text articles, and did their quality assessment by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Then, quality synthesis of results was done. RESULTS: Twenty-six studies of economic evaluations met our inclusion criteria. The CHEERS scores for most studies (n=9) were 85 or higher (excellent quality). Eight studies scored 70 to 85 (good quality), eight studies scored 55 to 70 (average quality), and one study < %55 (poor quality). The decision-analytic modeling was applied to twenty-three studies (88%) to evaluate their services. Most studies utilized the SIR model for outcomes. In studies with long-time horizons, social distancing was more cost-effective than quarantine, non-intervention, and herd immunity. Personal protective equipment was more cost-effective in the short-term than non-intervention. Screening tests were cost-effective in all studies. CONCLUSION: The results suggested screening tests and social distancing to be cost-effective alternatives in preventing and controlling COVID-19 on a long-time horizon. However, evidence is still insufficient and too heterogeneous to allow any definite conclusions regarding costs of interventions. Further research as are required in the future. The COVID-19 pandemic has influences worldwide communities with considerable morbidity 32 and mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(1-3). 33 This disease causes dry cough, fever, breath shortness, pneumonia, and lung infections(4). 34 Healthcare systems have raised some concerns regarding the high demand for increasing the 35 existing capacity, additional resources, and financial support(5). 36 Years of Life Lost (YLLs) due to COVID-19 were 4,072,325 in 30 high-incidence countries on 37 July 14, 2020. The largest number of total YLLs attributed to COVID-19 was in the USA, and 38 the YLLs and Disability-Adjusted Life Years (DALYs) per 100,000 populations were the highest 39 in Belgium(6). In Korea, the Years Lost due to Disability (YLDs) and the YLLs constituted 40 10.3% and 89.7% of the DALYs, respectively (3) . 41 YLL causes most burden of COVID-19 and suggests that decision-makers should make an effort 42 to reduce fatality. It emphasizes the importance of early identification of incidence cases (3, 6) . 43 Global economic costs of COVID-19 are estimated from $77 billion to $2.7 trillion(7). The 44 direct medical cost of an asymptomatic COVID-19 patient was $3,045 during the infection in the 45 USA(5). 46 No vaccine or approved treatment has been found for the prevention and treatment of COVID-47 19. Any attempt to achieve treatment should be widely available and cost-effective to control this 48 global pandemic(7). Effectiveness Analysis Registry (CEA). We developed a search strategy to detect studies using a 74 Population/Problem-Intervention-Comparison-Outcomes-Study design (PICOS) framework. 75 We used Medical Subject Heading (Mesh) terms and keywords for "cost" and "COVID-19". Search strategy for all databases is presented in Appendix S1. We also searched reference lists of 77 included studies to identify relevant articles. First, the search strategy was developed for PubMed 78 and afterward translated to other databases. The included studies specifically focused on 79 economic analysis of strategies and programs against COVID-19. The detailed exclusion and 80 inclusion criteria are presented in Table 1 . 81 We initially screened the title and abstract of retrieved studies based on inclusion/exclusion 82 criteria. Then, two researchers independently evaluated the full-text of the eligible articles. In 83 cases that the disagreement could not be resolved, the viewpoints of the third researcher used. 84 We designed a data extraction form including country, compared interventions, study population, 85 J o u r n a l P r e -p r o o f 4 time horizon, type of economic evaluation (CEA, cost-utility analysis, and cost-benefit analysis), 86 perspective, costs, and outcomes. The reporting quality of the economic evaluation studies was assessed by the CHEERS 88 checklist(12). Items were scored as "fully met", "not meet", "partially met", or "not applicable". Studies that fully met each of the items of the checklist were scored as '1', items that partially met the 90 criteria 0.5 and 0 when the study did not meet the criteria. 91 Then a percentage score for each study was calculated. Quality scoring ≥ 85% were categorized as 92 having excellent reporting quality, 70-85% as very good quality, 55 -70% as good quality, and quality 93 scoring < 55% were classified as poor quality. Two researchers (A.R, A.S) independently assessed The PRISMA flow diagram of this study is given in Figure 1 . In total, 2176 records were 103 identified from all databases. After the removal of all duplicate records, 649 studies were eligible 104 based on screening the titles and abstracts. Afterward, according to the inclusion criteria, 70 105 articles were selected for full-text evaluation. Finally, a total of 26 publications were included in 106 the qualitative analysis, whose characteristics have been presented in Table 2 and Table 3 . The most frequent items that were not reported in the articles implied item 6 'study perspective' 149 (54% no compliant), item 18 'study parameters' (54% no compliant), and item 24 'conflicts of The discounting rate for costs and benefits were at 3% to 5 % annually. Five studies have not 162 stated the discount rate(31, 34-36, 38). 164 The results regarding the cost-effectiveness of the interventions in prevention, control, and 165 treatment of COVID-19 are summarized in Table 2 . Indian study, lockdown was found to be cost-saving as 2.7 trillion(30). In another Indian study, 213 the net benefit of lockdown was reported in all scenarios ranging from 667.25 to 10038.69(31). In one American study, the value of life lost by social distance and its net benefit were $ 21.8 215 and $ 5.9 trillion, respectively(14). Another American study regarding the monetary value of 216 QALY gained from social distancing was 1143.9 billion compared to herd immunity(16). results of studies was difficult (e.g., preventive and diagnostic procedures, also drug therapies). Results of the present study showed that in research with long-time horizons, the social 227 distancing was more cost-effective than quarantine, non-intervention, and herd immunity. For Personal protective equipment was more cost-effective in the short-time than non-intervention. There was no long-term study regarding the cost-effectiveness of personal protective equipment. 275 The authors declared that they have no conflict of interest. This paper was written independently, no company or institution supported it financially. Provenance and peer review Not commissioned, externally peer-reviewed. Older Adults and the Economic Impact of the COVID-19 Pandemic China: a cost and affordability analysis Korea Using Disability-Adjusted Life Years Unique Identifying number or registration ID Author contribution Please specify the contribution of each author to the paper, e.g. study design, data collections, data analysis, writing. Others, who have contributed in other ways should be listed as contributors. Conceptualization: Aziz Rezapour, Aghdas Souresrafil. Project administration: Aziz Rezapour. Data extraction: Aziz Rezapour, Aghdas Souresrafil. Quality assessment: Aziz Rezapour The authors declare that they have no conflict of interest. This paper was written independently; no company or institution supported it financially. This study requires formal ethical approval because it will not involve the collection of primary data. Please enter the name of the registry, the hyperlink to the registration and the unique identifying number of the study. You can register your research at http://www.researchregistry.com to obtain your UIN if you have not already registered your study. This is mandatory for human studies only. The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. Please note that providing a guarantor is compulsory. J o u r n a l P r e -p r o o f AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both For Yes:Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? For Partial Yes: For Yes: The authors state that they had a written As for partial yes, plus the protocol protocol or guide that included ALL the should be registered and should also following:have specified: For Yes, either ONE of the following: □ at least two reviewers independently agreed on selection of eligible studies □ Yes and achieved consensus on which studies to include □ No □ OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one reviewer.J o u r n a l P r e -p r o o f AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both For Yes □ □ either ONE of the following: at least two reviewers achieved consensus on which data to extract from included studies OR two reviewers extracted data from a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder extracted by one reviewer. For Partial Yes: For Yes, must also have: □ provided a list of all potentially □ Justified the exclusion from □ Yes relevant studies that were read the review of each potentially □ Partial Yes in full-text form but excluded relevant study □ No from the review For Partial Yes (ALL the following):For Yes, should also have ALL the following: □ described populations □ described population in detail □ Yes □ described interventions □ described intervention in □ Partial Yes □ described comparators detail (including doses where □ No □ described outcomes relevant) □ described comparator in detail □ described research designs (including doses where relevant) □ described study's setting □ timeframe for follow-up individual studies that were included in the review? For Partial Yes, must have assessed RoB For Yes, must also have assessed RoB from from:□ unconcealed allocation, and □ allocation sequence that was □ Yes □ lack of blinding of patients and not truly random, and □ Partial Yes assessors when assessing □ selection of the reported result □ No outcomes (unnecessary for from among multiple □ Includes only objective outcomes such as all-measurements or analyses of a NRSI cause mortality) specified outcome NRSI For Partial Yes, must have assessed For Yes, must also have assessed RoB: RoB:□ methods used to ascertain □ Yes □ from confounding, and exposures and outcomes, and □ Partial Yes □ from selection bias □ selection of the reported result □ No from among multiple □ Includes only measurements or analyses of a RCTs specified outcome □ Must have reported on the sources of funding for individual studies included □ Yes in the review. Note: Reporting that the reviewers looked for this information □ No but it was not reported by study authors also qualifies J o u r n a l P r e -p r o o f AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both 11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? RCTs For Yes:□ The authors justified combining the data in a meta-analysis □ AND they used an appropriate weighted technique to combine study results and adjusted for heterogeneity if present. □ AND investigated the causes of any heterogeneityNo meta-analysis conducted For NRSI For Yes:□ The authors justified combining the data in a meta-analysis □ Yes □ AND they used an appropriate weighted technique to combine □ No study results, adjusting for heterogeneity if present □ No meta-analysis □ AND they statistically combined effect estimates from NRSI that conducted □ were adjusted for confounding, rather than combining raw data, or justified combining raw data when adjusted effect estimates were not available AND they reported separate summary estimates for RCTs and NRSI separately when both were included in the review For Yes: □ performed graphical or statistical tests for publication bias and discussed □ Yes the likelihood and magnitude of impact of publication bias J o u r n a l P r e -p r o o f As this article is a systematic review, all research data are available in the tables, figures and articles cited in the references.